1887

Abstract

Human immunodeficiency virus type 1 (HIV-1) can be either resistant or sensitive to complement- mediated destruction depending on the host cells. Incorporation of different levels of host cell CD46, CD55 and CD59 may account for this differential sensitivity to complement. However, it has not been determined whether CD46, CD55 and CD59 can all be incorporated at levels which protect virions. To determine whether each of these proteins can protect HIV-1, virions were derived from CHO cells expressing either human CD46, CD55 or CD59. Virions were shown to incorporate both glycosyl phosphatidylinositol (GPI)-anchored CD55 and CD59 as well as transmembrane CD46. Importantly, all three virus preparations were significantly more resistant to complement lysis than control virus. This study demonstrates that HIV-1 incorporates both transmembrane and GPI-anchored complement control proteins from host cells and that both types of protein increase complement resistance of virus.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-78-8-1907
1997-08-01
2022-01-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/78/8/9266986.html?itemId=/content/journal/jgv/10.1099/0022-1317-78-8-1907&mimeType=html&fmt=ahah

References

  1. Adachi A., Gendelman H. E., Koenig S., Folks T., Willey R., Rabson A., Martin M. A. 1986; Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. Journal of Virology 59: 284–291
    [Google Scholar]
  2. Arthur L. O., Bess J. W.Jr Sowder R. C.II Benveniste R. E., Mann D. L., Chermann J. -C., Henderson L. E. 1992; Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258:1935–1938
    [Google Scholar]
  3. Franke E. K., Yuan H. E. H., Luban J. 1994; Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372:359–362
    [Google Scholar]
  4. Fujita T., Inoue T., Ogawa K., Iida K., Tamura N. 1987; The mechanism of action of decay-accelerating factor (DAF) : DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. Journal of Experimental Medicine 166:1221–1228
    [Google Scholar]
  5. Gomez M. B., Hildreth J. E. K. 1995; Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1. Journal of Virology 69: 4628–4632
    [Google Scholar]
  6. Kojima A., Iwata K., Seya T., Matsumoto M., Ariga H., Atkinson J. P., Nagasawa S. 1993; Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3- fragment deposition and cytolysis. Journal of Immunology 151:1519–1527
    [Google Scholar]
  7. Liszewski M. K., Atkinson J. P. 1992; Membrane cofactor protein. Current Topics in Microbiology and Immunology 4:8–13
    [Google Scholar]
  8. Lublin D. M., Coyne K. E. 1991; Phospholipid -anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement- mediated cell damage. Journal of Experimental Medicine 174:35–44
    [Google Scholar]
  9. Lublin D. M., Liszewski M. K., Post T. W., Arce M. A., Le Beau M. M., Rebentisch M. B., Lemons R. S., Seya T., Atkinson J. P. 1988; Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP) : evidence for inclusion in the multigene family of complement-regulatory proteins. Journal of Experimental Medicine 168:181–194
    [Google Scholar]
  10. Marschang P., Sodroski J., Wurzner R., Dierich M. P. 1995; Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 inactivation by human complement. European Journal of Immunology 25:285–290
    [Google Scholar]
  11. Medof M. E., Lublin D. M., Holers V. M., Ayers D. J., Getty R. R., Leykam J. F., Atkinson J. P., Tykocinski M. L. 1987; Cloning and characterization of cDNAs encoding the complete sequence of decay accelerating factor of human complement. Proceedings of the National Academy of Sciences USA: 842007–2011
    [Google Scholar]
  12. Meri S. 1994; Protectin (CD59): complement lysis inhibitor and prototype domain in a new protein superfamily. Immunologist 2:149–155
    [Google Scholar]
  13. Montefiori D. C., Cornell R. J., Zhou J. Y., Zhou J. T., Hirsch V. M., Johnson P. R. 1994; Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immuno-deficiency viruses and possible targets for vaccine protection. Virology 205:82–92
    [Google Scholar]
  14. Orentas R. J., Hildreth J. E. K. 1993; Association ofhost cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Research and Human Retroviruses 9: 1157–1165
    [Google Scholar]
  15. Palker T. J., Clark M. E., Langlois A. J., Matthews T. J., Weinhold K. J., Randall R. R., Bolognesi D. P., Haynes B. F. 1988; Type- specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proceedings of the National Academy of Sciences USA: 85 1932–1936
    [Google Scholar]
  16. Rollins S. A., Sims P. J. 1990; The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. Journal of Immunology 144:3478–3483
    [Google Scholar]
  17. Saifuddin M., Parker C. J., Peeples M. E., Gorny M. K., Zolla-Pazner S., Ghassemi M., Rooney I. A., Atkinson J. P., Spear G. T. 1995; Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. Journal of Experimental Medicine 182:501–509
    [Google Scholar]
  18. Seya T., Ballard L. N., Bora N., Cui W., Kumar B. V., Atkinson J. P. 1988; Distribution of membrane cofactor protein (MCP) of complement on human peripheral blood cells. European Journal of Immunology 18:1289–1294
    [Google Scholar]
  19. Sullivan B. L., Knopoff E. J., Saifuddin M., Takefman D. M., Saarloos M. -N., Sha B. E., Spear G. T. 1996; Susceptibility virus to complement-mediated lysis: evidence for a role in clearance of virus in vivo. Journal of Immunology 157:1791–1798
    [Google Scholar]
  20. Terstappen L. W. M., Nguyen M., Lazarus H. M., Medof M. E. 1992; Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation. Journal of Leukocyte Biology 52:652–660
    [Google Scholar]
  21. Zhao J., Rollins S. A., Maher S. E., Bothwell A. L. M., Sims P. J. 1991; Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. Journal of Biological Chemistry 266:13418–13422
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-78-8-1907
Loading
/content/journal/jgv/10.1099/0022-1317-78-8-1907
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error